Cullinan Therapeutics Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, Cullinan Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $32.36. The average 1-year stock price forecast is 51.85% higher than the current stock price, while the lowest is $23 (+7.93%) and the highest is $42 (+97.09%).

Price Target: $32.36 (+51.85%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$23	$32.36	$30	$42
Change	+7.93%	+51.85%	+40.78%	+97.09%

Analyst Ratings

The average analyst rating for Cullinan Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	11	11	11	11	11	10
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	12	12	12	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sean Laaman Morgan Stanley	Morgan Stanley	Buy Reiterates $30	Buy	Reiterates	$30	+40.78%	Aug 17, 2026
David Dai UBS	UBS	Buy Maintains $24 → $27	Buy	Maintains	$24 → $27	+26.70%	Aug 17, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $30	Buy	Reiterates	$30	+40.78%	Aug 17, 2026
Alex Thompson CFA Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $28	Buy	Maintains	$28	+31.39%	Aug 13, 2026
Kaveri Pohlman Clear Street	Clear Street	Buy Reiterates $46 → $47	Buy	Reiterates	$46 → $47	+120.55%	Aug 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

13.88M

Revenue Next Year

38.23M

from 13.88M

175.49%

from 13.88M

EPS This Year

-3.17

from -3.36

EPS Next Year

-2.71

from -3.17

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	18.94M	-	-	-	-	13.88M
Operating Income	-67.95M	-132.14M	-190.65M	-196.92M	-241.65M	-221.43M
Net Income	-65.57M	111.21M	-153.16M	-167.38M	-219.88M	-216.58M
EPS	-	-	-	-	-3.36	-3.17
Free Cash Flow	-24.64M	-47.60M	-88.76M	-84.86M	-100.28M	-168.00M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	104.0M
Avg	13.9M
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	1,108.2%
Avg	175.5%
Low	-100.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-1.85
Avg	-3.17
Low	-3.86

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-